Tradestie Institutional Equity Comparison Engine

ABVC vs CONX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABVC Overall Edge

ABVC Captures Institutional Edge (2โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ABVC BioPharma, Inc. Common Stock (ABVC) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ABVC trades at N/M Forward P/E with 0.0% operating margin (+104.5% YoY revenue) versus CONX at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABVC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CONX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABVC N/M vs CONX N/M Fwd P/E
Growth & Margin Winner ABVC
Op Margin 0.0% vs N/A ยท YoY +104.5% vs N/A
Momentum & Technical Winner ABVC
1Y -66.4% vs -89.0% ยท 52W Pos 10% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ABVC NASDAQ
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.94
+3.3% 1D
Market Cap $24.5M
1M Return +2.41%
1Y Return -66.43%
Forward P/E N/M
Unified AI Score
39.0 / 100 SELL
Tech 32.0 Fund 37.0 Flow 50.0 Mom 40.0
CONX US Equity
CONX
Institutional Equity
$2.66
-11.75% 1D
Market Cap N/A
1M Return -54.66%
1Y Return -88.97%
Forward P/E N/M
Unified AI Score
42.0 / 100 HOLD
Tech 25.0 Fund 54.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABVC -66.43% CONX -88.97% Spread: +23.53 pp (ABVC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABVC TTM Op. Margin: 0.0% CONX TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs CONX. Trailing 12-month operating profitability (ABVC 0.0% vs CONX N/A) and valuation multiples (ABVC N/M vs CONX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABVC (7) vs CONX (1)
Institutional Metric ABVC CONX Criterion Row Winner
Market Capitalization Scale $24.5M N/A Larger Scale ABVC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +104.5% N/A Higher Growth ABVC
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin ABVC
Net Profit Margin Profitability 0.0% N/A Higher Margin ABVC
Return on Equity (ROE) Capital Efficiency -52.7% N/A Higher ROE ABVC
52-Week Range Position Momentum 10% ($1โ€“$3) 0% ($3โ€“$28) Stronger Trend ABVC
Beta / 30D Volatility Risk Regime 1.34ฮฒ ยท 56% Vol 4.88ฮฒ ยท 135% Vol Lower Realized Risk ABVC
Unified Institutional Score Composite Signal 39.0 / 100 (SELL) 42.0 / 100 (HOLD) Higher Composite CONX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABVC vs CONX Buy Guide
ABVC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ABVC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CONX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CONX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABVC nor CONX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.